Connect with us

Cannabis News

Maine Officials Approve 2026 Ballot Initiative To Largely Repeal Marijuana Legalization Law For Signature Collection

Published

on

Maine officials have given permission to prohibition activists to begin gathering signatures for a proposal A ballot initiative that would roll back the state’s voter-approved marijuana legalization law. The measure, if passed, would also overhaul the regulatory structure of the medical cannabis program by establishing product testing requirements.

The proposal — called the “Cannabis Legalization Act and Maine Medical Use of Cannabis Act” — is a revamped version of a marijuana initiative introduced in September, sponsored by a Republican state senator and a former top staffer for then-Gov. Paul LePage (R), staunch prohibitionist.

The latest proposal, a petition approved by the Secretary of State on Monday, would remove and amend multiple sections of the current state statute, which voters approved in 2016 to effectively repeal the legalization of recreational marijuana sales.

Adults over the age of 21 would remain legal to possess 2.5 ounces of cannabis under the proposal, but a section of the law allowing home cultivation would be repealed. The sale and home cultivation of medical marijuana would be legal.

Madison Carey, who was listed as a lead petitioner in the original version of the repeal initiative and remains involved in the current campaign, told Marihuana Momenti on Tuesday that “there needs to be regulation of marijuana,” arguing that her own experience recovering from opioid misuse disorder speaks to the inadequacy of the current law.

“My hope is to raise awareness of the reality of the potential dangers of not having regulation,” he said. “I think people are fed up with the constant use — the constant (retail businesses) coming up where people can legally buy marijuana.”

Of course, repealing the voter-approved law that established the adult-licensed sales system would eliminate the current regulatory infrastructure in place, which reform advocates say helps mitigate public health and safety risks associated with the illegal market.

Rep. David Boyer (R), who led the fight to get a cannabis legalization initiative on Maine’s ballot in 2016 when he was a staff member at the Marihuana Policy Project, said voters should refuse to sign petitions for the new initiative.

“Don’t stop Maine’s progress, don’t stop signing this unfair repeal initiative,” he told Marijuana Moment on Tuesday. “Repealing the legalization of cannabis would shut down an industry larger than lobsters, potatoes and blueberries combined, costing our state jobs, revenue and economic growth.”

According to the new measure, the director of the Office of Cannabis Policy will “advance policies that promote the health and welfare of the people of the state and protect their health and safety, emphasizing the health and welfare of minors as a priority consideration in the performance of all duties.”

They should also “ensure that eligible patients maintain access to high-quality, effective, and affordable medical cannabis under this Act.”

Under the proposal, the Department of Administrative and Financial Services would create a testing program for cannabis products that would require dispensaries and dispensaries to send those products to a licensed facility for safety evaluation before dispensing them to qualified patients.

The testing facility “should ensure that cannabis or cannabis products do not exceed acceptable levels of contamination for any contaminants that are harmful to health and require testing and ensure proper labeling.”

“The department shall adopt rules establishing a testing program under this section, rules identifying the types of pollutants harmful to health, which must be tested for cannabis and cannabis products under this chapter, and rules regarding the maximum level of contamination for each pollutant,” the vote said. the initiative the text says

Additionally, regulators should administer a system to track cannabis plants from seed to the point of retail sale or disposal. That system “should be able to track cannabis plants in groups during the cultivation phase and when passing from the cultivation phase to another registrar”.

Entrepreneurs must submit at least 67,682 valid voter signatures by February 2, 2026 to be eligible for next year’s ballot. If approved by voters, the initiative would take effect on January 1, 2028.


It’s Marijuana Moment tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Maine lawmakers passed a bill in June legalize possession of an ounce of psilocybin Adults over 21 years of age.

After a different effort in the state last year legalize psilocybin and allow adults to access the psychedelic in state-licensed facilities. But lawmakers watered down that bill—instead, they changed it to create a committee to study further reforms—and in the end it was not approved.

Meanwhile, Maine legislators in February A top marijuana official voted to investigate possible conflicts of interest.

And last year, the law that allowed people came into force now apply for legal marijuana crime records to be sealed.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Missouri cannabis growers file class action against Good Day Farm

Published

on

By

CPC of Missouri-Smithville, LLC and GF Saint Mary LLC, licensed cannabis growers and manufacturers in Missouri, filed a lawsuit in the Circuit Court of Jackson County on behalf of independent wholesalers, alleging that Good Day Farm (GDF) and its network of conspiring companies and investors were harmed by an intentional, coordinated and unconstitutional scheme. The complaint alleges that the “GDF Cartel” illegally controls or manages the state’s share of dispensary licenses and uses that market power to manipulate Missouri’s $1.52 billion cannabis market for its own profit.

GDF and its co-conspirators allegedly built the cartel by arranging for third parties to invest in limited liability companies (LLCs) that then acquire additional dispensaries, cultivation and processing facilities, all of which are owned, operated or controlled by GDF. The result: The alleged cartel exercises effective control over at least 61 dispensaries, nearly triple the 22 allowed by the Missouri Constitution, with more than 10% of dispensary licenses “under substantially common control, ownership or management.” With 224 dispensaries currently licensed statewide, the alleged GDF Cartel controls more than one in four dispensary licenses in Missouri. But its influence is even greater, with alleged Cartel dispensaries accounting for more than 40% of wholesale cannabis in the state, giving it significant — and illegal — influence over all independent growers and manufacturers forced to sell through its network.

To avoid the Missouri Constitution’s 10% licensing limit and avoid regulatory oversight, the alleged cartel operates under five different brand names:

  • Good Day Farm (21 dispensaries),
  • CODES (20 dispensaries),
  • Green light (10 dispensaries),
  • Fresh Karma (6 dispensaries), and
  • 3 Fifteen Primo (4 medications).

But they’re all part of a single, coordinated operation, the complaint says.

  • Purchase cannabis products from non-Cartel wholesalers at artificially depressed prices;
  • They supply their 61 dispensaries with the same products—mainly those produced by Cartel growers—significantly excluding products from independent wholesalers;
  • Force independent drug wholesalers to purchase the Cartel’s finished products as a condition for their wholesale products to be placed on the Cartel’s drug store shelves; and
  • Boycott non-cartel wholesalers who refuse to agree to anti-cartel demands.

Bob Hoffman, one of the attorneys leading the case, said: “The GDF Cartel is removing competition from the wholesale cannabis market and enriching itself with illegal profits through a counterproductive, clandestine business conspiracy. Missouri growers and manufacturers have been suffering under this scheme for a long time; many of them know something is wrong, but we don’t realize how the cartel has manipulated the market through this manipulation framework. Missourians to approve recreational cannabis in 2022 They voted for a fair and competitive market. Missouri licensed cannabis businesses that have suffered these practices should join us because they may be entitled to substantial damages.”

The complaint alleges the financial toll the Cartel has taken: Since the Cartel began illegal price-fixing, it has used its collective market power to lower wholesale prices by more than 20%, and continues to squeeze wholesalers and threaten the viability of their operations.

The unconstitutional complaint alleges that GDF knew its plan to build cartels could create legal risks for the company under the Constitution’s 10% licensing limit. The complaint quotes from a document provided by GDF to potential investors: “There can be no assurance that the Missouri Department of Cannabis Regulation will not dispute the number of marijuana dispensaries operated or supervised by the operator or its affiliates…”.

This action is brought on behalf of a putative class that includes all licensed independent wholesalers in Missouri that are not members of the alleged GDF Cartel for purposes of injunctive relief. Wholesalers who believe they have been financially harmed by the alleged Cartel’s practices should join the case because they may be entitled to substantial damages. The putative class is represented by the law firms of Feuerstein Kulick LLP and Bryan Cave Leighton Paisner LLP.

Source: Feuerstein Kulick LLP and Bryan Cave Leighton Paisner LLP

Continue Reading

Cannabis News

State-Licensed Marijuana Businesses Can Now Apply For Federal Protections Using New DEA Form

Published

on

By

State licensee Medical marijuana companies can apply for federal protections In line with the Trump administration’s cannabis reprogramming process.

The Drug Enforcement Administration’s “Medical Marijuana Dispensary Registry Portal” went live Wednesday morning.

The move comes after the Justice Department announced that last week Marijuana Schedule I through III of the Controlled Substances Act (CSA), in stages.

Pursuant to an order signed by Attorney General Blanche, marijuana products regulated by a state medical cannabis license were immediately moved to Title III.

III. State-licensed medical cannabis dispensaries that wish to take advantage of the new legal protections and tax benefits that come with annexation status must first file an application with the DEA requesting information about their processes for storage, ordering, distribution, inventory, record keeping and other aspects of their business.

For each activity below, indicate whether the company has a standard operating procedure (SOP):

    • the order
    • receiving
    • Inventories
    • Marijuana storage
    • security
    • Distribution (including delivery services)
    • to divide
    • Destruction/Disposal
    • Reporting Theft/Loss
    • Due diligence (including provider/patient/professional verification)
    • Corresponding Liability
    • Record keeping”

The application asks about specific details of security measures such as vaults, safes, secure storage, access controls, alarm systems and on-site security personnel.

Applicants can choose whether to apply for administration of marijuana, marijuana extracts, or naturally derived delta-9 THC.

Currently, with only medical marijuana moving to Schedule III, the application asks potential registrants whether their businesses handle or provide recreational marijuana.

According to last week’s DOJ order, an expedited administrative hearing process will be held beginning June 29 to consider the broader cannabis reorganization.

The DEA application, meanwhile, also asks companies to submit information about their state’s cannabis licenses and to answer questions about their criminal and disciplinary history.

It also asks, “Has anyone involved in the ownership or operation of the business previously manufactured, distributed, and/or provided a controlled substance without a DEA registration authorizing such activity?”

Allegedly every illegal cannabis company operating in the state today has key employees who have done so, medical marijuana was a Schedule I substance whose manufacture, distribution and general distribution was not permitted by the DEA until just a few days ago.

Applicants must also list the suppliers from whom they plan to procure marijuana, and report whether they plan to repackage or relabel cannabis products.

They must also provide lists of people whose business they expect to have “access to controlled substances,” including their dates of birth, social security numbers, and drug-related criminal histories.

“Provide the following for each person you plan to acquire controlled substances:

    • The name
    • Title(s)
    • date of birth
    • Social Security number
    • DEA registration numbers, if applicable
    • State/territory permits to manufacture, distribute, dispense, or otherwise handle controlled substances
    • Has this person been subject to one or more federal, state, territorial, or tribal disciplinary actions?
    • Has this person been convicted of federal, state, territorial, tribal, or local offenses related to controlled substances?

There is also $794 per year the application fee, currently only payable through PayPal, although DEA ​​”expects to have additional payment methods in the coming weeks.”

Application fees are non-refundable.

Separately, the DEA has launched a new web page on its website that contains key information about the new federal rescheduling move for cannabis, including copies of Federal Register orders outlining the process for the amendment and the upcoming litigation.

Blanche’s reorganization order last week said that to comply with the international drug control treaty’s “requirement that a government agency act as the exclusive purchaser of cannabis production,” the DOJ is setting in motion a process by which the federal government technically buys from marijuana producers and then sells to them or related entities.

“Registered growers must store the crops in a DEA-accessible facility until that transaction is completed, and each grower’s registration must specify the area in which the grow is allowed,” he said.

“All manufacturers registered under this subsection shall establish a nominal price for the purchase of their marijuana crops. The Administration shall then purchase the entity’s crops at that price and resell the crops to the entity, or a related or supporting entity, at the same price plus the administrative fee calculated in section 1318.06(a)..”

Meanwhile, the US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after the reorganization announcement.

The reorganization will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

White House Press Secretary Karoline Leavitt said the administration is moving forward with the marijuana overhaul because Cannabis reform is “very popular” with voters and because doing so will help people who need access to the drug for medical purposes.

At the press event held in the Oval Office last week, President Donald Trump spoke about the medical benefits of marijuana.

“A lot of people are facing big problems, and that seems to be the best answer,” he said. “They’re very happy. So the reorganization begins, and that’s a big thing, the reprogramming.”

The president stated that his administration’s rescheduling of cannabis came about after his friend Howard Kessler told him about his use of medical marijuana.

“He had some medical difficulties, and it came about by chance, kind of,” he said. “He had to go through a lot of different medications, and he said this was the one that was so much better than anything else. And so he lived through that. He didn’t benefit from it, because now he lives much better from the perspective.”

“So we hope you don’t have to,” Trump said. “But if you must, I hear it’s the best of all alternatives.”

Separately, the president asked Congress to take action changing the law that threatens to federally recriminalize hemp-derived full-spectrum CBD products later this year

“We need to do this STRAIGHT and FAST, especially for those who have found CBD helping them,” he said in a social media post. “Also, I’m told it will help our BIG FARMERS that we love and will always be around.”

A few days ago, Trump denounced this Federal officials were “slowly” pursuing his cannabis warrant.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Klasmann-Deilmann announces management changes

Published

on

By











After fifteen years of successful cooperation, managing director Moritz Böcking and the shareholders of Klasmann-Deilmann GmbH have mutually agreed to part ways. As of May 1, 2026, Moritz Böcking will hand over the position of managing director to Jan Astrup, who served as the company’s CEO in 2021/2022. Jan Astrup and Damian Ikemann will form the Board of Directors of the Klasmann-Deilmann Group from now on.

© Klasmann-Deilmann Benelux

Klasmann-Deilmann thanks Moritz Böcking for his cooperation and the progress achieved in the transformation of the Klasmann-Deilmann Group. Moritz Böcking expanded Klasmann-Deilmann beyond the growing media business into new areas of commercial horticulture and promoted innovation and digitalization within the company. In addition, its achievements include the expansion of resources derived from renewable raw materials, as well as the acquisition of a subsidiary in Australia and production facilities in France and Canada, which operate in cooperation with external partners. He also significantly advanced Klasmann-Deilmann’s positioning as a global pioneer of sustainable development in the growing media industry, thereby making a decisive contribution to the company’s economic growth.

With Jan Astrup, Klasmann-Deilmann is getting an internationally experienced manager who has proven himself in the company and has extensive experience in raw materials, production, process optimization and technology. With the new CEO, raw materials and technology-driven areas for the substrate industry are now increasingly important at senior management level. Jan Astrup will strengthen the core commercial horticulture business and help develop the company for the future.

For more information:
Klasmann-Deilmann GmbH
(email protected)
www.klasmann-deilmann.com



Publication date:













Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media